Torque, an immuno-oncology company, has introduced a high-efficiency T cell manufacturing process, called Slipstream. The Slipstream process is now in place at UC Davis for manufacturing Deep-Primed T-Cells for Torque’s first clinical trial planned for later this year in both solid and hematologic cancers. “Torque’s cell manufacturing strategy is a critical aspect of our mission to dramatically expand cell therapy cures for cancer,” said Bart Henderson, chief executive...